|
Quidel to Present at 31st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, CA, Jan 02, 2013 (MARKETWIRE via COMTEX) --
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid
diagnostic testing solutions and cellular-based virology assays,
announced today that it will present at the 31st Annual J.P. Morgan
Healthcare Conference to be held at The Westin St. Francis hotel in
San Francisco, California on Wednesday, January 9, 2013.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present that day at 10:30 a.m.
Eastern time (7:30 a.m. Pacific time) with a question and answer
session scheduled immediately following the presentation. During the
presentation, the company will discuss business and financial
developments and trends. The company's statements may contain or
constitute material information that has not been previously
disclosed.
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company's Web
site at www.quidel.com. Participants should allow approximately five
to ten minutes prior to the presentation's start time to visit the
site and download any streaming media software needed to listen to
the Internet webcast. A replay of the webcast will also be available
on the company's Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of
people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
QuickVue(R), D3(R) Direct Detection and Thyretain(R) leading brand
names, as well as under the new Sofia(R) and AmpliVue(R) brands,
Quidel's products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal occult blood. Quidel's research and development
engine is also developing a continuum of diagnostic solutions from
advanced lateral-flow and direct fluorescent antibody to molecular
diagnostic tests to further improve the quality of healthcare in
physicians' offices and hospital and reference laboratories. For more
information about Quidel's comprehensive product portfolio, visit
www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
Quidel Contact:
Quidel Corporation
Randy Steward
Chief Financial Officer
(858) 552-7931
Media and Investors Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023
Email Contact
SOURCE: Quidel
http://www2.marketwire.com/mw/emailprcntct id=FADACE913CCB5AD4
[ InfoTech Spotlight's Homepage ]
|